Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer
Status:
Terminated
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
This trial is designed to enroll postmenopausal patients with locally advanced or metastatic,
HER2- and HR+ breast cancer not amenable to curative treatment by surgery or radiotherapy,
and whose disease has progressed on or after prior endocrine therapy.
Patients must undergo molecular pre-screening prior to entry.